Spectrum Pharmaceuticals, Inc. (OQ:SPPI)

Business Focus: Biotechnology & Medical Research

Jul 29, 2022 07:00 am ET
Spectrum Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the second quarter 2022 financial results and provide a corporate update on Thursday, August 11, 2022 at 8:30 a.m. Eastern/5:30 a.m. Pacific.
Jun 02, 2022 07:00 am ET
Spectrum Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in two upcoming investor conferences:
May 26, 2022 05:01 pm ET
Spectrum Pharmaceuticals to Present Data at 2022 ASCO Highlighting the Potential Predictive Capabilities of ctDNA as a Biomarker for Poziotinib Treatment Response
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced additional exploratory data for poziotinib in non-small cell lung cancer (NSCLC) patients harboring HER2 exon 20 insertion mutations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from June 3-7.
May 17, 2022 07:00 am ET
Spectrum Pharmaceuticals to Participate in H.C. Wainwright Global Investment Conference
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the upcoming H.C. Wainwright Global Investment Conference, to be held virtually and in Miami Beach from May 23-26, 2022. A presentation will be available on the Investor Relations section of the company’s website at
May 12, 2022 04:00 pm ET
Spectrum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended March 31, 2022 and provided a corporate update.
May 11, 2022 07:00 am ET
Spectrum Pharmaceuticals Appoints Nora E. Brennan as Chief Financial Officer
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Nora Brennan as Chief Financial Officer effective May 25, 2022. Ms. Brennan has served on Spectrum’s Board of Directors and as Chairperson of the Audit Committee since December 2020, and will relinquish her Board duties to assume this new role.
May 06, 2022 07:00 am ET
Spectrum Pharmaceuticals to Report First Quarter 2022 Financial Results and Provide Corporate Update
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2022 financial results and provide a corporate update on Thursday, May 12, 2022 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
May 05, 2022 07:00 am ET
Spectrum Pharmaceuticals Appoints Brittany K. Bradrick to Board of Directors
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Brittany Bradrick to its Board of Directors. Brittany is an accomplished leader with 25 years of finance, strategy and corporate development experience.
Apr 11, 2022 09:31 am ET
Thinking about buying stock in Hoth Therapeutics, Spectrum Pharmaceuticals, Datto Holding, Bilibili, or Hycroft Mining?
NEW YORK, April 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HOTH, SPPI, MSP, BILI, and HYMC.
Apr 11, 2022 07:00 am ET
Spectrum Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for Eflapegrastim
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the resubmitted Biologics License Application (BLA) for eflapegrastim has been accepted for filing. The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) goal date of September 9, 2022. Spectrum is seeking an indication to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically signifi
Apr 04, 2022 07:00 am ET
Spectrum Pharmaceuticals Announces Poster Presentation at the Upcoming AACR Annual Meeting
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced abstract acceptance with a poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to be held in New Orleans from April 8-13, 2022.
Mar 24, 2022 08:31 am ET
Thinking about buying stock in Nikola Corp, D-Market Electronic Services, Biondvax Pharmaceuticals, Trip.com, or Spectrum Pharmaceuticals?
NEW YORK, March 24, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NKLA, HEPS, BVXV, TCOM, and SPPI.
Mar 24, 2022 08:30 am ET
Optimism Builds for Promising Developments & New Drug Therapies Targeting Treatments for Breast Cancer
PALM BEACH, Fla., March 24, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The status of breast cancer as one of the most commonly occurring cancers in the world is expected to be a key driving factor for the global market. As more and more patients are diagnosed with breast cancer across the globe, the need for accurate and efficient treatment outcomes for the patient remains unparalleled. Furthermore, the strong trend of continuous R&D amongst key market players engaged in breast cancer therapeutics would lead to the launch of breakthrough therapeutics in the coming year
Mar 21, 2022 09:31 am ET
Thinking about buying stock in BlackBerry, VEON, Ultrapar Participacoes, Spectrum Pharmaceuticals, or ThredUp?
NEW YORK, March 21, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BB, VEON, UGP, SPPI, and TDUP.
Mar 17, 2022 04:00 pm ET
Spectrum Pharmaceuticals Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Corporate Update
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period and full year ended December 31, 2021.
Mar 11, 2022 07:00 am ET
Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2021 financial results and provide a corporate update on Thursday, March 17, 2022 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
Mar 10, 2022 07:00 am ET
Spectrum Pharmaceuticals Appoints Juhyun Lim of Hanmi Pharmaceutical to Board of Directors
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Juhyun Lim to its Board of Directors.
Mar 07, 2022 06:00 am ET
Spectrum Pharmaceuticals Presents Positive Data for Poziotinib in First-line NSCLC Patients with HER2 Exon 20 Insertion Mutations
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the presentation of safety and efficacy results from Cohort 4 of the ZENITH20 clinical trial. This data is from 70 first-line patients with non-small lung cancer (NSCLC) with HER2 exon 20 insertion mutations who received 16 mg daily, given as 16 mg once daily (48 patients) or 8 mg twice daily (22 patients) of oral poziotinib. These results showed a confirmed objective response rate (ORR) of 41% (95% CI:30%-54%), as evaluated centrally by an independent image
Feb 28, 2022 07:00 am ET
Spectrum Pharmaceuticals Announces an Oral Poziotinib Presentation at the Upcoming ESMO TAT 2022 Virtual Meeting
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced an oral presentation on poziotinib at the European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies (TAT) Congress 2022 being held virtually March 7-8, 2022. Details of the presentation are as follows:
Feb 11, 2022 07:00 am ET
Spectrum Pharmaceuticals Announces Acceptance of New Drug Application Filing for Poziotinib
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that its New Drug Application (NDA) for poziotinib has been accepted for review by the U.S. Food and Drug Administration (FDA).
Jan 26, 2022 05:44 pm ET
Constellation Energy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
NEW YORK, Jan. 26, 2022 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600:
Jan 20, 2022 07:00 am ET
Spectrum Pharmaceuticals to Participate in B. Riley Securities 2022 Virtual Oncology Conference
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the B. Riley Securities 2022 Virtual Oncology Conference. A fireside chat is scheduled for Thursday, January 27, 2022 at 9:30 a.m. ET / 6:30 a.m. PT.
Jan 14, 2022 09:30 am ET
Thinking about buying stock in China SXT Pharmaceuticals, Virgin Galactic, Citigroup, Novavax, or Spectrum Pharmaceuticals?
NEW YORK, Jan. 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SXTC, SPCE, C, NVAX, and SPPI.
Jan 05, 2022 08:00 am ET
Spectrum Pharmaceuticals Announces Strategic Restructuring
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a strategic restructuring. The company will prioritize its late-stage product opportunities, poziotinib and ROLONTIS® (eflapegrastim), and will deprioritize development activities of its early-stage clinical development and research programs. The company has made these decisions following a detailed review of its operations, portfolio and growth opportunities, and will focus its resources accordingly.
Jan 04, 2022 07:00 am ET
Spectrum Pharmaceuticals Announces New Strategic Investment by Hanmi Pharmaceutical
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a $20 million equity investment by Hanmi Pharmaceutical along with revisions to the licensing agreements for ROLONTIS® (eflapegrastim) and poziotinib. Under the terms of the strategic investment, Hanmi entered into a $20 million equity purchase agreement that will be priced at $1.60 per share.
Dec 15, 2021 08:07 am ET
Did You Acquire (SPPI) Before December 27, 2018? Should Spectrum Pharmaceuticals Management be Held Accountable for Investors Losses? Contact Johnson Fistel
Johnson Fistel, LLP is investigating potential claims on behalf of Spectrum Pharmaceuticals, Inc. ("Spectrum" or "the Company") (NASDAQ: SPPI) against certain of its officers and directors. Recently, a class action complaint was filed against...
Dec 06, 2021 07:00 am ET
Spectrum Pharmaceuticals Submits New Drug Application for Poziotinib
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that it has submitted its New Drug Application (NDA) for poziotinib to the U.S. Food and Drug Administration (FDA) for use in patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2 exon 20 insertion mutations. The NDA submission is based on the positive results of Cohort 2 from the ZENITH20 clinical trial, which assessed the safety and efficacy of poziotinib. The product has received Fast Track designation
Dec 01, 2021 04:00 pm ET
Spectrum Pharmaceuticals Announces Changes to Management Team and Board of Directors
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that Tom Riga, currently Chief Commercial and Chief Operating Officer, will be the next President and CEO effective December 31, 2021. Mr. Riga will also join the company’s Board of Directors upon assuming his new role. Spectrum and Joseph Turgeon, President and CEO, have agreed that Mr. Turgeon will retire from Spectrum on December 31, 2021, after nine years with the company. Accordingly, he will also be stepping down from Spectrum’s Board of Directors
Nov 30, 2021 07:00 am ET
Spectrum Pharmaceuticals to Participate in JMP Securities Hematology and Oncology Summit
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the JMP Securities Hematology and Oncology Summit, a virtual presentation is scheduled for Tuesday, December 7, 2021 at 2:40 p.m. ET / 11:40 a.m. PT.
Nov 11, 2021 07:00 am ET
Spectrum Pharmaceuticals to Participate in 2021 Jefferies London Healthcare Conference
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the 2021 Jefferies London Healthcare Conference. A virtual fireside chat will be available to conference attendees, on-demand beginning on Thursday, November 18, 2021, at 3 a.m. ET / 8 a.m. GMT.
Nov 10, 2021 04:00 pm ET
Spectrum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Update
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced financial results for the three-month period ended September 30, 2021 and provided a corporate update.
Nov 03, 2021 07:00 am ET
Spectrum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Provide Corporate Update
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the third quarter 2021 financial results and provide a corporate update on Wednesday, November 10, 2021 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
Nov 03, 2021 06:02 am ET
SHAREHOLDER ALERT: Robbins LLP Investigates Spectrum Pharmaceuticals, Inc. (SPPI) for Misleading Shareholders
Shareholder rights law firm Robbins LLP is investigating Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) to determine whether certain Spectrum officers and directors violated the Securities Exchange Act of 1934. Spectrum is a biopharmaceutical company that develops and commercializes oncology and hematology drug products
Nov 01, 2021 02:11 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc of Class Action Lawsuit and Upcoming Deadline – SPPI
Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc (“Spectrum” or the “Company”) (NASDAQ: SPPI) and certain of its officers.   The class action, filed in the United States District Court for the...
Nov 01, 2021 12:15 pm ET
DEADLINE ALERT for SPPI and LDI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Nov 01, 2021 11:06 am ET
SPECTRUM DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Spectrum Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) in the United States District Court for the District of Nevada on behalf of all persons and entities who purchased or otherwise acquired Spectrum securities between December 27, 2018 and August 5, 2021, both dates inclusive (the “Class Period”). Investors have until November 1, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Oct 30, 2021 01:18 pm ET
SPPI FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important Monday Deadline in Securities Class Action – SP
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 27, 2018 and August 5, 2021, inclusive (the “Class Period”), of the important...
Oct 29, 2021 02:23 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. (SPPI)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 1, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Spectrum Pharmaceuticals, Inc....
Oct 29, 2021 11:00 am ET
Final Days to Participate in Spectrum Pharmaceuticals, Inc. (SPPI) Class Action - Bronstein, Gewirtz & Grossman, LLC
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. ("Spectrum” or the "Company") (NASDAQ: SPPI) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Spectrum securities between December 27, 2018 and August 5, 2021, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:
Oct 27, 2021 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Spectrum and loanDepot and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) and loanDepot, Inc. (NYSE: LDI)....
Oct 27, 2021 12:30 pm ET
DEADLINE ALERT for SPPI, LDI, SAM: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Oct 26, 2021 03:45 pm ET
SHAREHOLDER FILING DEADLINE: NOVEMBER 1, 2021 SPECTRUM PHARMACEUTICALS, INC. (NASDAQ: SPPI) CLASS ACTION LAWSUIT DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plain
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the November 1, 2021 deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or...
Oct 26, 2021 03:00 pm ET
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Spectrum Pharmaceuticals, Inc. (SPPI) Investors
LOS ANGELES, Oct. 26, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) securities between December 27, 2018 and August 5, 2021, inclusive (the "Class Period"). Spectrum investors have until November 1, 2021 to file a lead plaintiff motion.
Oct 26, 2021 12:15 pm ET
DEADLINE ALERT for SPPI and LDI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Oct 26, 2021 10:00 am ET
SPPI, LDI & LGVN Upcoming Class Action Deadlines - Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Oct 25, 2021 11:38 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc of Class Action Lawsuit and Upcoming Deadline - SPPI
NEW YORK, Oct. 25, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc ("Spectrum" or the "Company") (NASDAQ: SPPI) and certain of its officers. The class action, filed in the United States District Court for the District of Nevada, and docketed under 21-cv-01612, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Spectrum securities between December 27, 2018 and August 5, 2021, both dates inclusive (the "Class Period"), seeking to recover damages c
Oct 23, 2021 01:14 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important November 1 Deadline in Securities Class Action – SPPI
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 27, 2018 and August 5, 2021, inclusive (the “Class Period”), of the important November...
Oct 22, 2021 11:30 am ET
SPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit
BENSALEM, Pa., Oct. 22, 2021 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI).
Oct 20, 2021 07:11 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc of Class Action Lawsuit and Upcoming Deadline – SPPI
Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc (“Spectrum” or the “Company”) (NASDAQ: SPPI) and certain of its officers.   The class action, filed in the United States District Court for the...
Oct 20, 2021 03:30 pm ET
INVESTOR ALERT: SPECTRUM PHARMACEUTICALS, INC. (NASDAQ: SPPI) CLASS ACTION LAWSUIT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securi
NEW YORK, Oct. 20, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the November 1, 2021 deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) from December 27, 2018 through August 5, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the District of Nevada alleges violations of the Securities Act of 1934.
Oct 20, 2021 12:30 pm ET
DEADLINE ALERT for SAVA, SPPI, LDI, SAM: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Oct 19, 2021 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Katapult, HyreCar, Spectrum, and loanDepot and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Katapult Holdings, Inc. (NASDAQ: KPLT), HyreCar Inc. (NASDAQ: HYRE), Spectrum...
Oct 19, 2021 12:00 pm ET
DEADLINE ALERT for SPPI and LDI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Oct 19, 2021 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. (SPPI)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 1, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Spectrum Pharmaceuticals, Inc....
Oct 18, 2021 06:12 pm ET
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important November 1 Deadline in Securities Class Action – SPPI
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 27, 2018 and August 5, 2021, inclusive (the “Class Period”), of the important November 1,...
Oct 18, 2021 04:30 pm ET
INVESTOR ALERT: SPPI INVESTOR LAWSUIT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Spectrum Ph
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Oct 15, 2021 08:50 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc of Class Action Lawsuit and Upcoming Deadline - SPPI
NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc ("Spectrum" or the "Company") (NASDAQ: SPPI) and certain of its officers.  The class action, filed in the United States District Court for the District of Nevada, and docketed under 21-cv-01612, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Spectrum securities between December 27, 2018 and August 5, 2021, both dates inclusive (the "Class Period"), seeking to recover damages
Oct 14, 2021 01:49 pm ET
DEADLINE ALERT for SAVA, SPPI, LDI, SAM: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Oct 13, 2021 10:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Katapult, HyreCar, Spectrum, and loanDepot and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Katapult Holdings, Inc. (NASDAQ: KPLT), HyreCar Inc. (NASDAQ: HYRE), Spectrum...
Oct 13, 2021 04:32 pm ET
SPECTRUM PHARMACEUTICALS, INC. (NASDAQ: SPPI) FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Spe
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Oct 13, 2021 04:08 pm ET
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important November 1 Deadline in Securities Class Ac
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 27, 2018 and August 5, 2021, inclusive (the “Class Period”), of the important November 1,...
Oct 13, 2021 12:10 pm ET
DEADLINE ALERT for SPPI and LDI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Oct 12, 2021 11:59 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. (SPPI)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 1, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Spectrum Pharmaceuticals, Inc....
Oct 11, 2021 04:14 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc of Class Action Lawsuit and Upcoming Deadline – SPPI
Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc (“Spectrum” or the “Company”) (NASDAQ: SPPI) and certain of its officers. The class action, filed in the United States District Court for the...
Oct 09, 2021 10:00 am ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important November 1 Deadline in Securities Class Action – SPPI
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 27, 2018 and August 5, 2021, inclusive (the “Class Period”), of the important November 1, 2021 lead plaintiff deadline.
Oct 09, 2021 09:40 am ET
(SPPI) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel About Leading Spectrum Pharmaceuticals, Inc. Class Action Lawsuit
Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Spectrum Pharmaceuticals, Inc. ("Spectrum Pharmaceuticals” or the "Company") (NASDAQ: SPPI). The class action is on behalf...
Oct 07, 2021 10:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ATI, View, and Spectrum and Encourages Investors to Contact the Firm
Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of ATI Physical Therapy, Inc. (NYSE: ATIP), View, Inc. (NASDAQ: VIEW), and Spectrum...
Oct 07, 2021 07:01 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc of Class Action Lawsuit and Upcoming Deadline - SPPI
NEW YORK, Oct. 7, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc ("Spectrum" or the "Company") (NASDAQ: SPPI) and certain of its officers. The class action, filed in the United States District Court for the District of Nevada, and docketed under 21-cv-01612, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Spectrum securities between December 27, 2018 and August 5, 2021, both dates inclusive (the "Class Period"), seeking to recover damages ca
Oct 07, 2021 10:00 am ET
DEADLINE ALERT for SAVA, SPPI, LDI, SAM: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Oct 07, 2021 09:00 am ET
Spectrum Pharmaceuticals Announces Presentation of Poziotinib in Combination with KRASG12C Inhibitors at the 2021 AACR-NCI-EORTC Conference
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the presentation of preclinical data demonstrating the synergistic impact of poziotinib when combined with KRAS inhibitors in KRASG12C mutant specific cell lines. Jacqulyne Robichaux, Ph.D., Assistant Professor, University of Texas, MD Anderson Cancer Center is presenting a poster titled “Pan-ErbB inhibition enhances activity of KRASG12C inhibitors in preclinical models of KRASG12C mutant cancers” at the Virtual International
Oct 06, 2021 12:15 pm ET
SPPI INVESTOR CLASS ACTION LAWSUIT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Spectrum Pharm
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Oct 06, 2021 11:00 am ET
SPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit
LOS ANGELES, Oct. 6, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI)
Oct 05, 2021 01:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. (SPPI)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 1, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Spectrum Pharmaceuticals, Inc....
Oct 04, 2021 10:20 am ET
SHAREHOLDER ALERT: Robbins LLP Reminds Investors that Spectrum Pharmaceuticals, Inc. (SPPI) is Being Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) securities between December 27, 2018 and August 5, 2021, for violations of the Securities Exchange Act of 1934.
Oct 03, 2021 06:47 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc of Class Action Lawsuit and Upcoming Deadline – SPPI
Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc (“Spectrum” or the “Company”) (NASDAQ: SPPI) and certain of its officers. The class action, filed in the United States District Court for the...
Oct 02, 2021 08:00 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ATI, View, and Spectrum and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of ATI Physical Therapy, Inc. (NYSE: ATIP), View, Inc. (NASDAQ: VIEW), and Spectrum...
Oct 01, 2021 03:10 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors With Losses Exceeding $100K to Secure Counsel Before Important November 1 Deadline in Securities Class Action – SPPI
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 27, 2018 and August 5, 2021, inclusive (the “Class Period”), of the important November...
Oct 01, 2021 11:00 am ET
DEADLINE ALERT for SAVA, SPPI, LDI, SAM: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 30, 2021 12:35 pm ET
DEADLINE ALERT for SPPI and LDI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 29, 2021 08:33 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc of Class Action Lawsuit and Upcoming Deadline - SPPI
NEW YORK, Sept. 29, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc ("Spectrum" or the "Company") (NASDAQ: SPPI) and certain of its officers. The class action, filed in the United States District Court for the District of Nevada, and docketed under 21-cv-01612, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Spectrum securities between December 27, 2018 and August 5, 2021, both dates inclusive (the "Class Period"), seeking to recover damages
Sep 27, 2021 09:09 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Iterum, View, and Spectrum and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Iterum Therapeutics plc (NASDAQ: ITRM), View, Inc. (NASDAQ: VIEW), and Spectrum...
Sep 27, 2021 01:10 pm ET
SPECTRUM PHARMACEUTICALS, INC. (NASDAQ: SPPI) CLASS ACTION FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsui
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Sep 27, 2021 10:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. (SPPI)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 1, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Spectrum Pharmaceuticals, Inc....
Sep 25, 2021 12:18 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important November 1 Deadline in Securities Class Action – SPPI
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 27, 2018 and August 5, 2021, inclusive (the “Class Period”), of the important November 1,...
Sep 24, 2021 11:00 am ET
DEADLINE ALERT for SAVA, SPPI, LDI, SAM: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 23, 2021 08:23 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc of Class Action Lawsuit and Upcoming Deadline – SPPI
Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc (“Spectrum” or the “Company”) (NASDAQ: SPPI) and certain of its officers. The class action, filed in the United States District Court for the...
Sep 23, 2021 01:00 pm ET
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. (SPPI)
BENSALEM, Pa., Sept. 23, 2021 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming November 1, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) securities between December 27, 2018 and August 5, 2021, inclusive (the "Class Period").
Sep 23, 2021 11:50 am ET
DEADLINE ALERT for SPPI and LDI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 22, 2021 09:07 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Iterum, View, and Spectrum and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Iterum Therapeutics plc (NASDAQ: ITRM), View, Inc. (NASDAQ: VIEW), and Spectrum...
Sep 22, 2021 07:00 am ET
Spectrum Pharmaceuticals to Participate in 2021 Cantor Virtual Global Healthcare Conference
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the 2021 Cantor Virtual Global Healthcare Conference. A fireside chat is scheduled for Wednesday, September 29, 2021, at 1:20 p.m. ET.
Sep 21, 2021 07:22 pm ET
ROSEN, A TOP RANKED LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – SPPI
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 27, 2018 and August 5, 2021, inclusive (the “Class Period”), of the important November 1,...
Sep 20, 2021 12:15 pm ET
SPPI CLASS ACTION DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc.
NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) from December 27, 2018 through August 5, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the District of Nevada alleges violations of the Securities Act of 1934.
Sep 20, 2021 11:00 am ET
DEADLINE ALERT for SAVA, SPPI, LDI: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 20, 2021 08:30 am ET
Thinking about buying stock in Verastem, Corvus Pharmaceuticals, Aprea Therapeutics, Spectrum Pharmaceuticals, or SmileDirectClub?
NEW YORK, Sept. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VSTM, CRVS, APRE, SPPI, and SDC.
Sep 19, 2021 10:48 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc of Class Action Lawsuit and Upcoming Deadline - SPPI
NEW YORK, Sept. 19, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc ("Spectrum" or the "Company") (NASDAQ: SPPI) and certain of its officers. The class action, filed in the United States District Court for the District of Nevada, and docketed under 21-cv-01612, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Spectrum securities between December 27, 2018 and August 5, 2021, both dates inclusive (the "Class Period"), seeking to recover damages
Sep 18, 2021 08:45 am ET
Spectrum Pharmaceuticals Presents Late Breaker Oral Presentation of Poziotinib Data in First-Line NSCLC Patients with HER2 Exon 20 Insertion Mutations at ESMO Congress 2021
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the presentation of safety and efficacy results from Cohort 4 of the ZENITH20 clinical trial. This data is from 48 first-line patients with non-small cell lung cancer (NSCLC) with HER2 exon 20 insertion mutations who received 16mg of oral poziotinib once daily. These results showed a confirmed objective response rate (ORR) of 44%, as evaluated centrally by an independent image review committee using RECIST 1.1 criteria. The data was presented as a late
Sep 17, 2021 04:40 pm ET
SPECTRUM PHARMACEUTICALS, INC. (NASDAQ: SPPI) LAWSUIT DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Sp
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Sep 17, 2021 11:35 am ET
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Spectrum Pharmaceuticals, Inc. (SPPI) Investors
LOS ANGELES, Sept. 17, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) securities between December 27, 2018 and August 5, 2021, inclusive (the "Class Period"). Spectrum investors have until November 1, 2021 to file a lead plaintiff motion.
Sep 17, 2021 11:15 am ET
DEADLINE ALERT for SPPI and LDI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 15, 2021 08:58 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coinbase, Annovis Bio, and Spectrum and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Coinbase Global Inc. (NASDAQ: COIN), Annovis Bio, Inc. (NYSE: ANVS), and...
Sep 15, 2021 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. (SPPI)
LOS ANGELES , Sept. 15, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming November 1, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Spectrum Pharmaceuticals, Inc.  ("Spectrum" or the "Company") (NASDAQ: SPPI) securities between December 27, 2018 and August 5, 2021, inclusive (the "Class Period").
Sep 13, 2021 08:15 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SPPI
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 27, 2018 and August 5, 2021, inclusive (the “Class Period”), of the important November 1,...
Sep 13, 2021 03:45 pm ET
LAWSUIT FILED: SPECTRUM PHARMACEUTICALS Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information
Block & Leviton announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) for potential securities law violations. Investors who purchased shares and have lost money are encouraged to contact the...
Sep 13, 2021 11:00 am ET
SPPI Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Spectrum Pharmaceuticals, Inc. Investors of Class Action and Encourages Investors to Contact the Firm
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. ("Spectrum” or the "Company") (NASDAQ: SPPI) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Spectrum securities between December 27, 2018 and August 5, 2021, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:
Sep 13, 2021 08:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc of Class Action Lawsuit and Upcoming Deadline - SPPI
NEW YORK, Sept. 13, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc ("Spectrum" or the "Company") (NASDAQ: SPPI) and certain of its officers. The class action, filed in the United States District Court for the District of Nevada, and docketed under 21-cv-01612, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Spectrum securities between December 27, 2018 and August 5, 2021, both dates inclusive (the "Class Period"), seeking to recover damages
Sep 13, 2021 07:00 am ET
Spectrum Pharmaceuticals Announces Late-Breaking Oral Presentation of Data for Poziotinib in First-Line NSCLC Patients with HER2 Exon 20 Mutations at the Upcoming ESMO Congress 2021
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a late-breaking presentation of early poziotinib efficacy and safety data in first-line patients with non-small cell lung cancer (NSCLC) with HER2 exon 20 mutations from cohort 4 of the ZENITH20 clinical trial at the upcoming European Society for Medical Oncology Congress (ESMO) 2021 that will take place virtually September 16-20, 2021.
Sep 11, 2021 09:10 am ET
ALERT: Spectrum Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Case - SPPI
SAN DIEGO, Sept. 11, 2021 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) securities between December 27, 2018 and August 5, 2021, inclusive (the "Class Period") have until November 1, 2021 to seek appointment as lead plaintiff in the Spectrum Pharmaceuticals class action lawsuit.  The Spectrum Pharmaceuticals class action lawsuit charges Spectrum Pharmaceuticals and certain of its top executives with violations of the Securities Exchange Act of 1934.  The Spectrum Pharmaceuticals class action lawsui
Sep 09, 2021 06:33 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc of Class Action Lawsuit and Upcoming Deadline – SPPI
Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc (“Spectrum” or the “Company”) (NASDAQ: SPPI) and certain of its officers.   The class action, filed in the United States District Court for the...
Sep 09, 2021 01:00 pm ET
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. (SPPI)
Law Offices of Howard G. Smith reminds investors of the upcoming November 1, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) securities between December 27, 2018 and August 5, 2021, inclusive (the “Class Per
Sep 09, 2021 10:00 am ET
SPPI Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Spectrum Pharmaceuticals, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. ("Spectrum” or the "Company") (NASDAQ: SPPI) and certain of its officers, on behalf of...
Sep 08, 2021 09:04 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coinbase, Annovis Bio, and Spectrum and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Coinbase Global Inc. (NASDAQ: COIN), Annovis Bio, Inc. (NYSE: ANVS), and...
Sep 08, 2021 05:10 pm ET
SPPI DEADLINE: Spectrum Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
Robbins Geller Rudman & Dowd LLP announces that purchasers of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) securities between December 27, 2018 and August 5, 2021, inclusive (the “Class Period”) have until November 1, 2021 to seek appointment as lead plaintiff in the Spectrum
Sep 08, 2021 10:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. (SPPI)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 1, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ:
Sep 07, 2021 11:01 pm ET
SPPI ALERT: Spectrum Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
SAN DIEGO, Sept. 7, 2021 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers and acquirers of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) securities between December 27, 2018 and August 5, 2021, inclusive (the "Class Period") have until November 1, 2021 to seek appointment as lead plaintiff in the Spectrum Pharmaceuticals class action lawsuit.  The Spectrum Pharmaceuticals class action lawsuit charges Spectrum Pharmaceuticals and certain of its top executives with violations of the Securities Exchange Act of 1934.  The Spectrum Pharmaceuticals class action lawsui
Sep 07, 2021 08:15 pm ET
SPPI INVESTOR NOTICE: ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Secur
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 27, 2018 and August 5, 2021, inclusive (the “Class Period”), of the important November 1, 2021 lead plaintiff deadline.
Sep 07, 2021 03:22 pm ET
SPECTRUM PHARMACEUTICALS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the
Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the District of Nevada on behalf of persons and entities that purchased or otherwise acquired...
Sep 07, 2021 12:15 pm ET
SPPI INVESTOR LAWSUIT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Spectrum Pharmaceuticals, I
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Sep 07, 2021 11:30 am ET
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Spectrum Pharmaceuticals, Inc. (SPPI) Investors
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ:
Sep 07, 2021 10:00 am ET
SHAREHOLDER ALERT: Robbins LLP Announces that Spectrum Pharmaceuticals, Inc. (SPPI) is Being Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) securities between December 27, 2018 and August 5, 2021, for violations of the Securities Exchange Act of 1934. Spectrum is a
Sep 05, 2021 04:30 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spectrum Pharmaceuticals, Inc of Class Action Lawsuit and Upcoming Deadline - SPPI
NEW YORK, Sept. 5, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc ("Spectrum" or the "Company") (NASDAQ: SPPI) and certain of its officers. The class action, filed in the United States District Court for the District of Nevada, and docketed under 21-cv-01612, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Spectrum securities between December 27, 2018 and August 5, 2021, both dates inclusive (the "Class Period"), seeking to recover damages c
Sep 03, 2021 04:00 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Spectrum Pharmaceuticals, Inc. (SPPI) Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ:
Sep 03, 2021 01:00 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Spectrum Pharmaceuticals, Inc. (SPPI) Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) securities between December 27, 2018 and August 5, 2021, inclusive (the “Class Period”). Spectrum investors have until November 1, 2021 to
Sep 03, 2021 12:45 pm ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact
LOS ANGELES, Sept. 3, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ("Spectrum" or "the Company") (NASDAQ: SPPI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Sep 02, 2021 08:00 pm ET
SPECTRUM ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Spectrum Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) in the United States District Court for the District of Nevada on behalf of all persons and entities who purchased or otherwise acquired Spectrum securities between December 27, 2018 and August 5, 2021, both dates inclusive (the “Class Period”). Investors have until November 1, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Sep 02, 2021 04:30 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Spectrum Pharmaceuticals, Inc. (SPPI) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ:
Sep 02, 2021 03:20 pm ET
The Law Offices of Frank R. Cruz Announces Investigation of Spectrum Pharmaceuticals, Inc. (SPPI) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ:
Sep 02, 2021 12:59 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Spectrum Pharmaceuticals, Inc. (SPPI) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) investors concerning the Company’s possible violations of federal securities laws.
Sep 02, 2021 10:00 am ET
SPPI Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Spectrum Pharmaceuticals, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm
NEW YORK, Sept. 2, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc.  ("Spectrum" or the "Company") (NASDAQ: SPPI) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Spectrum securities between December 27, 2018 and August 5, 2021, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/sppi.
Sep 02, 2021 09:34 am ET
SPPI DEADLINE: Investors with Substantial Losses Have Opportunity to Lead the Spectrum Pharmaceuticals, Inc. Class Action Lawsuit
SAN DIEGO, Sept. 2, 2021 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that the Spectrum Pharmaceuticals class action lawsuit charges Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) and certain of its top executives with violations of the Securities Exchange Act of 1934. The Spectrum Pharmaceuticals class action lawsuit seeks to represent purchasers of Spectrum Pharmaceuticals securities between December 27, 2018 and August 5, 2021, inclusive (the "Class Period"). The Spectrum Pharmaceuticals class action lawsuit was commenced on August 31, 2021 in the District of Nevada and i
Sep 01, 2021 08:03 pm ET
SPPI INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Spectrum Pharmaceuticals, Inc.
NEW YORK, Sept. 1, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) from December 27, 2018 through August 5, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the District of Nevada alleges violations of the Securities Act of 1934.
Sep 01, 2021 05:08 pm ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Spectrum Pharmaceuticals, Inc. (SPPI)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. (“Spectrum Pharmaceuticals” or the “Company”) (NASDAQ: SPPI) in the United States District Court for the District of Nevada on...
Sep 01, 2021 04:58 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact t
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. (“Spectrum” or “the Company”) (NASDAQ:
Sep 01, 2021 04:04 pm ET
SPPI ALERT: Investors With Substantial Losses Have Opportunity to Lead the Spectrum Pharmaceuticals, Inc. Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that purchasers of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) securities between December 27, 2018 and August 5, 2021, inclusive (the “Class Period”) have until November 1, 2021 to seek appointment as lead plaintiff in the Spectrum
Sep 01, 2021 03:56 pm ET
ROSEN, A LEADING NATIONAL FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SPPI
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 27, 2018 and August 5, 2021,...
Sep 01, 2021 09:57 am ET
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action –
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 27, 2018 and August 5, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 1, 2021.
Aug 31, 2021 10:16 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action Against Spectrum Pharmaceuticals, Inc and Certain Officers - SPPI
NEW YORK, Aug. 31, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc ("Spectrum" or the "Company") (NASDAQ: SPPI) and certain of its officers. The class action, filed in the United States District Court for the District of Nevada, and docketed under 21-cv-01612, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Spectrum securities between December 27, 2018 and August 5, 2021, both dates inclusive (the "Class Period"), seeking to recover damages c
Aug 24, 2021 09:29 am ET
SPECTRUM PHARMACEUTICALS INVESTIGATION: Block & Leviton Investigates Spectrum Pharmaceuticals For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
Block & Leviton is investigating Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) for potential securities law violations. Investors who have lost money in their Spectrum Pharmaceuticals investment should contact the firm to learn more about how they...
Aug 15, 2021 08:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spectrum Pharmaceuticals, Inc. - SPPI
Pomerantz LLP is investigating claims on behalf of investors of Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext....
Aug 12, 2021 04:05 pm ET
Spectrum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Update
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced financial results for the three-month period ended June 30, 2021 and provided a corporate update.
Aug 11, 2021 05:37 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spectrum Pharmaceuticals, Inc. - SPPI
Pomerantz LLP is investigating claims on behalf of investors of Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext....
Aug 10, 2021 08:00 pm ET
SPECTRUM ALERT: Bragar Eagel & Squire, P.C. is Investigating Spectrum Pharmaceuticals, Inc. on Behalf of Spectrum Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) on behalf of Spectrum stockholders. Our investigation concerns whether Spectrum has violated the federal securities laws and/or engaged in other unlawful business practices.
Aug 09, 2021 08:33 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spectrum Pharmaceuticals, Inc. - SPPI
NEW YORK, Aug. 9, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Aug 06, 2021 01:06 pm ET
(SPPI) Alert: Did You Lose Money on Your Investment? Contact Johnson Fistel Regarding Investigation
SAN DIEGO, Aug. 6, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of the federal securities laws by Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI).
Aug 06, 2021 10:55 am ET
Thinking about buying stock in Sphere 3D, Norwegian Cruise Line, Zynga, electroCore, or Spectrum Pharmaceuticals?
NEW YORK, Aug. 6, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ANY, NCLH, ZNGA, ECOR, and SPPI.
Aug 06, 2021 07:30 am ET
Spectrum Pharmaceuticals Receives Complete Response Letter from FDA for ROLONTIS® (eflapegrastim)
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the company’s Biologics License Application (BLA) for ROLONTIS® (eflapegrastim). The CRL cited deficiencies related to manufacturing and indicated that a reinspection will be necessary. The company is seeking further clarification from the FDA and plans to meet with the agency as soon as possible.
Aug 05, 2021 06:00 am ET
Spectrum Pharmaceuticals to Report Second Quarter 2021 Financial Results and Provide Corporate Update  
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the second quarter 2021 financial results and provide a corporate update on Thursday, August 12, 2021 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
Jun 04, 2021 09:00 am ET
Spectrum Pharmaceuticals Presents Poziotinib Data in Patients with Brain Metastases from the ZENITH20 Clinical Trial at 2021 ASCO Annual Meeting
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today presented an e-poster on poziotinib CNS activity in patients with NSCLC with EGFR or HER2 exon 20 mutations. These data from Cohorts 1, 2 and 3 of the ongoing ZENITH20 clinical trial assessed the results from 36 patients with brain metastases at baseline with three patients (8%) achieving intracranial complete responses. The presentation titled “CNS activity of poziotinib in NSCLC with exon 20 insertion mutations” is available on the website for the 2021 ASCO Annual Me
Jun 01, 2021 07:00 am ET
Spectrum Pharmaceuticals Announces That the ROLONTIS® (eflapegrastim) Pre-Approval Inspection Has Been Initiated
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) is “on site” for the ROLONTIS® (eflapegrastim) manufacturing facility inspection. Spectrum previously received notification from the agency that it would defer its decision on the BLA for ROLONTIS because an inspection of the Hanmi Bioplant in South Korea could not be conducted due to restrictions on travel related to the COVID-19 pandemic.
May 28, 2021 07:00 am ET
Spectrum Pharmaceuticals to Present Data for Poziotinib in Patients with Brain Metastases at the Upcoming 2021 ASCO Annual Meeting
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation on poziotinib CNS activity in patients with NSCLC with EGFR or HER2 exon 20 mutations. This poster presentation will be available at the 2021 ASCO Annual Meeting being held June 4-8, 2021. Details of the presentation is as follows:
May 27, 2021 07:00 am ET
Spectrum Pharmaceuticals to Participate in Two Upcoming Investor Conferences in June
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at two upcoming virtual investor conferences:
May 13, 2021 04:00 pm ET
Spectrum Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Update
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended March 31, 2021 and provided a corporate update.
May 06, 2021 07:00 am ET
Spectrum Pharmaceuticals to Report First Quarter 2021 Financial Results and Provide Corporate Update
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2021 financial results and provide a corporate update on Thursday, May 13, 2021 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
Apr 10, 2021 08:30 am ET
Spectrum Pharmaceuticals Presents Additional Twice Daily Dosing Data for Poziotinib at the AACR Virtual Meeting 2021
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today presented a data update on the safety and tolerability of twice daily (BID) administered poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations. These preliminary data, from Cohort 5 of the ZENITH20 clinical trial, continue to show improved tolerability with BID dosing, reduced dose interruption compared to once daily (QD) dosing, and a reduction in treatment emergent Grade 3 or higher adverse events. The preliminary data also demonstrate improved a
Apr 05, 2021 07:00 am ET
Spectrum Pharmaceuticals Presentations at the Upcoming AACR Virtual Meeting 2021 to Include Updated Poziotinib Twice Daily Dosing Data
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation on safety and tolerability of twice daily administered poziotinib in patients with EGFR or HER2 exon 20 mutations. The company will also present a poster on the evaluation of same-day dosing of ROLONTIS® (eflapegrastim) in neutropenic rats and patients with early-stage breast cancer. These poster presentations will be available at the American Association for Cancer Research (AACR) Virtual Annual Meeting, taking place from Apr
Mar 30, 2021 04:00 pm ET
Spectrum Pharmaceuticals Reports Fourth Quarter 2020 and Full Year 2020 Financial Results and Pipeline Update
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period and full year ended December 31, 2020.
Mar 26, 2021 04:00 pm ET
Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2020 financial results and provide a corporate update on Tuesday, March 30, 2021 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
Mar 16, 2021 07:00 am ET
Spectrum Pharmaceuticals Provides Update on ROLONTIS® (eflapegrastim) Pre-Approval Inspection
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has scheduled the pre-approval inspection at the ROLONTIS® (eflapegrastim) manufacturing site in May 2021. In October 2020, the company received notification from the agency that it would defer its decision on the BLA because an inspection of the Hanmi Bioplant in South Korea could not be conducted during the review cycle due to restrictions on travel related to the COVID-19 pandemic.
Mar 11, 2021 07:00 am ET
FDA Grants Fast Track Designation to Spectrum Pharmaceuticals’ Poziotinib
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for poziotinib for the treatment of non-small cell lung cancer (NSCLC) in previously treated patients with HER2 exon 20 mutations. Spectrum plans to submit a new drug application (NDA) for poziotinib later this year.
Mar 02, 2021 11:45 am ET
Spectrum Pharmaceuticals Presents Twice Daily Dosing Data for Poziotinib at the ESMO TAT Virtual Congress 2021
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today presented results from Cohort 3 and initial twice daily (BID) dosing safety and efficacy data for poziotinib from Cohort 5 of the ZENITH20 clinical trial. These preliminary data demonstrate improved tolerability with BID dosing, reduced dose interruption compared to once daily (QD) dosing, and a reduction in treatment emergent Grade 3 or higher adverse events. The preliminary data also suggest improved anti-tumor activity with 8mg BID dosing. The presentation is part o
Feb 26, 2021 07:00 am ET
Spectrum Pharmaceuticals Announces Poster Presentation at Upcoming Miami Breast Cancer Conference
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation on interim safety evaluation of same-day dosing of ROLONTIS® (eflapegrastim) in patients with early-stage breast cancer receiving docetaxel and cyclophosphamide. This presentation will take place as part of the 38th Annual Miami Breast Cancer Conference® taking place virtually March 4-7, 2021. Details of the presentation are as follows:
Feb 23, 2021 07:00 am ET
Spectrum Pharmaceuticals Announces Two Presentations at Upcoming ESMO TAT Virtual Congress 2021
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced two presentations, one oral and one eposter, at the upcoming European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) Virtual Congress 2021. The oral presentation will provide some initial safety and efficacy data for poziotinib from the twice daily dosing cohort. The meeting takes place on March 1 – 2, 2021. Details of the presentations are as follows:
Feb 04, 2021 07:00 am ET
Spectrum Pharmaceuticals to Participate in Guggenheim Healthcare Talks 2021 Oncology Day
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day. The fireside chat is scheduled for Thursday, February 11, 2021, at 4 p.m. EST.
Jan 22, 2021 07:00 am ET
Spectrum Pharmaceuticals Announces Two Oral Presentations at Upcoming IASLC 2020 World Conference on Lung Cancer
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced an oral presentation on updated efficacy, safety, and dosing management of poziotinib from Cohorts 1 and 2 of the ZENITH20 clinical trial. In addition, Spectrum also announced an oral presentation on the structural classification of atypical EGFR mutations and their patterns of drug sensitivity. These presentations will take place as part of the IASLC 2020 World Conference on Lung Cancer (#WCLC20) hosted by the International Association for the Study of Lung
Jan 05, 2021 07:00 am ET
Spectrum Pharmaceuticals to Participate in Three Upcoming Investor Conferences in January
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will provide an overview of the company's business strategy and development-stage programs at three upcoming virtual investor conferences:
Dec 22, 2020 04:05 pm ET
Spectrum Provides Poziotinib Update after Successful Pre-NDA Meeting with the FDA
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has agreed to the submission of an NDA based on data from Cohort 2 of its Phase 2 clinical trial, ZENITH20, which evaluated previously treated patients with non-small cell lung cancer (NSCLC) with HER2 exon 20 insertion mutations. The company also reported that its pre-specified primary endpoint in its Phase 2 clinical trial evaluating poziotinib in first-line NSCLC patients with EGFR exon 20 insertion mu
Dec 17, 2020 08:00 am ET
BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors
BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Jeffrey Vacirca to its Board of Directors to help...
Dec 14, 2020 07:00 am ET
Spectrum Pharmaceuticals Appoints Nora Brennan to Board of Directors
Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Nora Brennan to its Board of Directors. Ms. Brennan fills a vacancy left by Ms. Elizabeth Czerepak, who retired from the Board effective December 10, 2020.
Dec 04, 2020 07:00 am ET
Spectrum Pharmaceuticals Announces Three Poster Presentations at Upcoming San Antonio Breast Cancer Symposium
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that three posters highlighting its drug development pipeline would be presented at the upcoming San Antonio Breast Cancer Conference (SABCS) to be held December 8 – 11, 2020.
Nov 09, 2020 07:00 am ET
Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in November
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at two upcoming virtual investor conferences:
Nov 04, 2020 04:00 pm ET
Spectrum Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Update
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended September 30, 2020.
Oct 28, 2020 07:00 am ET
Spectrum Pharmaceuticals to Report Third Quarter 2020 Financial Results and Provide Corporate Update
Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the third quarter 2020 financial results and provide a corporate update on Wednesday, November 4, 2020 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
Oct 26, 2020 07:00 am ET
Spectrum Pharmaceuticals Announces that the FDA is Deferring its Action on the BLA for ROLONTIS® (eflapegrastim)
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that an inspection of the Hanmi Bioplant in South Korea is required before the FDA can approve the company’s Biologics License Application (BLA) for ROLONTIS. The FDA was unable to conduct an inspection during the current review cycle due to restrictions on travel related to the COVID-19 pandemic. Therefore, the FDA is deferring action on the application until an inspection can be completed. The company will continue to work actively with the FDA to define an
Sep 18, 2020 07:00 am ET
Spectrum Pharmaceuticals Presents Results in HER2 Exon 20 Insertion Mutations from Cohort 2 of the Poziotinib ZENITH20 Clinical Trial
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today presented additional results from its pivotal Phase 2 clinical trial, ZENITH20, evaluating poziotinib in previously treated non-small cell lung cancer (NSCLC) patients with HER2 exon 20 insertion mutations (Cohort 2). The on-demand mini oral session is part of the European Society for Medical Oncology (ESMO) Virtual Congress 2020 Science Weekend being held September 19 – 21, 2020.
Sep 14, 2020 07:00 am ET
Spectrum Pharmaceuticals Announces Two Presentations for Poziotinib at ESMO Virtual Congress 2020
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a presentation of the results for Cohort 2 from its Phase 2 clinical trial, ZENITH20, evaluating poziotinib in previously treated non-small cell lung cancer (NSCLC) patients with HER2 exon 20 insertion mutations. In addition, a poster presentation of results from a single site expanded access program will also be presented for poziotinib in the treatment of patients with advanced NSCLC with EGFR or HER2 exon 20 insertion mutations. These presentations will ta
Sep 08, 2020 07:00 am ET
Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at two upcoming virtual investor conferences:
Aug 10, 2020 04:00 pm ET
Spectrum Pharmaceuticals Reports Second Quarter 2020 Financial Results and Corporate Update
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended June 30, 2020.
Aug 05, 2020 04:00 pm ET
Spectrum Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the underwriters of its previously announced public offering of common stock have fully exercised and closed on their option to purchase an additional 3,250,000 shares of the Company’s common stock at the public offering price of $3.00 per share, less underwriting discounts and commissions, for additional anticipated net proceeds to the Company of approximately $9.2 million. The option was granted in connection with the
Aug 03, 2020 07:00 am ET
Spectrum Pharmaceuticals to Report Second Quarter 2020 Financial Results and Provide Corporate Update
Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the second quarter 2020 financial results and provide a corporate update on Monday, August 10, 2020 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
Jul 30, 2020 07:00 am ET
Spectrum Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the pricing of an underwritten public offering of 21,666,667 shares of its common stock at a public offering price of $3.00 per share. The gross proceeds to Spectrum from this offering are expected to be approximately $65 million, before deducting underwriting discounts, commissions and estimated offering expenses. In addition, Spectrum has granted the underwriters a 30-day option to purchase up to an additional 3,250,000 sha
Jul 29, 2020 04:27 pm ET
Spectrum Pharmaceuticals Announces Proposed Public Offering of Common Stock
Spectrum Pharmaceuticals, Inc. (Nasdaq-GS: SPPI) (“Spectrum”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by Spectrum. Spectrum also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. The offering is subject to market and
Jul 28, 2020 09:31 am ET
Thinking about buying stock in Spectrum Pharmaceuticals, Sohu.com, Southwest Airlines, resTORbio, or Vaxart Inc?
NEW YORK, July 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SPPI, SOHU, LUV, TORC, and VXRT.
Jul 27, 2020 04:00 pm ET
Spectrum Pharmaceuticals Announces Positive Topline Results in HER2 Exon20 Insertion Mutations from Cohort 2 of the Poziotinib ZENITH20 Trial
Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that it met the pre-specified primary endpoint in the ZENITH20 Phase 2 clinical trial evaluating poziotinib in previously treated non-small cell lung cancer (NSCLC) patients with HER2 exon 20 insertion mutations (Cohort 2).
Jul 16, 2020 09:00 am ET
Tarsus Pharmaceuticals Announces Appointment of New COO and CFO
IRVINE, Calif., July 16, 2020 /PRNewswire/ -- Tarsus Pharmaceuticals, a clinical-stage biopharmaceutical company, today announced the appointment of two pharmaceutical veterans to its executive leadership team: Sesha Neervannan to the position of Chief Operating Officer (COO), and Leo Greenstein to the position of Chief Financial Officer (CFO). As part of its leadership, Sesha and Leo will help guide Tarsus Pharmaceuticals' corporate and product development, leveraging their proven knowledge, capabilities, and leadership skills to help Tarsus achieve its objectives.    
Jun 22, 2020 09:00 am ET
Spectrum Pharmaceuticals Presents Same Day Dosing Data for ROLONTIS® (eflapegrastim) at AACR Virtual Annual Meeting II
Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced preclinical data evaluating the administration of ROLONTIS® (eflapegrastim) on the same day as chemotherapy. The duration of neutropenia in a rat model of chemotherapy induced neutropenia (CIN) was observed to be significantly shorter with eflapegrastim versus pegfilgrastim, regardless of the timing of administration: concomitantly or on the same day post-chemotherapy at 2, 5 or 24 hours post-chemotherapy.
Jun 16, 2020 07:00 am ET
Spectrum Pharmaceuticals to Present Preclinical ROLONTIS® (eflapegrastim) Same Day Dosing Data at AACR Virtual Annual Meeting II
Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation of the results for preclinical studies evaluating the administration of ROLONTIS on the same day as chemotherapy in a rodent model. The abstract titled “Chemotherapy induced neutropenia in rats following administration of eflapegrastim or pegfilgrastim on the same day at three different timepoints and at 24 hours post-chemotherapy” will be part of the Special Populations, Survivorship, Outcomes, and Supportive Care session at the
Jun 03, 2020 04:00 pm ET
Spectrum Pharmaceuticals Appoints Lyndah K. Dreiling, M.D., MBA, as Senior Vice President, Clinical Development
Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that Lyndah K. Dreiling, M.D., MBA, has been named Senior Vice President, Clinical Development.
May 27, 2020 07:00 am ET
Spectrum Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference 2020
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at the Jefferies Virtual Healthcare Conference 2020. The fireside chat presentation is scheduled for Wednesday, June 3, 2020, at 9 a.m. EST.
May 07, 2020 04:00 pm ET
Spectrum Pharmaceuticals Reports First Quarter 2020 Financial Results and Pipeline Update
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended March 31, 2020.
May 01, 2020 07:00 am ET
Spectrum Pharmaceuticals to Report First Quarter 2020 Financial Results and Provide Corporate Update
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2020 financial results and provide a corporate update on Thursday, May 7, 2020 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
Apr 30, 2020 07:00 am ET
Spectrum Pharmaceuticals Initiates Same Day Dosing Clinical Trial for ROLONTIS® (eflapegrastim)
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced dosing of the first patient in a clinical trial to evaluate the administration of ROLONTIS on the same day as chemotherapy. The trial will evaluate the duration of severe neutropenia when administered at three different time points on the same day following standard chemotherapy in patients with early stage breast cancer. ROLONTIS is an investigational drug not approved by the U.S. Food and Drug Administration (FDA) and the BLA is curren
Apr 28, 2020 07:00 am ET
Spectrum Pharmaceuticals Provides Strategy Update for Poziotinib Development Program
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today provided an update on its ZENITH20 Phase 2 clinical trial evaluating poziotinib in non-small cell lung cancer (NSCLC) patients with EGFR and HER2 exon 20 insertion mutations. The protocol has been amended to explore additional twice daily dosing regimens as well as lower single daily dosage amounts. Earlier use of corticosteroids has also been added to the protocol in an effort to help patients better tolerate poziotinib and stay on therapy for a longer time. Previousl
Apr 23, 2020 07:00 am ET
Spectrum Pharmaceuticals Appoints Seth H.Z. Fischer to Board of Directors
Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Seth H.Z. Fischer to its Board of Directors. Mr. Fischer fills a vacancy left by Mr. Raymond Cohen, who retired from the Board effective April 22, 2020. Mr. Fischer will serve on the Board until the company’s next annual meeting of stockholders or until his respective successor is elected and qualified.
Apr 21, 2020 07:00 am ET
Spectrum Pharmaceuticals to Present Data from Phase 2 Clinical Trial for Poziotinib at American Association for Cancer Research Virtual Annual Meeting 2020
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the presentation of the results for Cohort 1 from its Phase 2 clinical trial, ZENITH20, evaluating poziotinib in previously treated non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations. The abstract titled “Poziotinib activity and durability of responses in previously treated EGFR exon 20 NSCLC patients - a Phase 2 study” will be part of the Lung Cancer Targeted Therapy session at the American Association for Cancer Research (AACR
Mar 17, 2020 07:00 am ET
Spectrum Pharmaceuticals Cancelled Participation in Upcoming Medical Conference Due to Coronavirus Pandemic
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that it had to cancel its planned presentation of Phase 2 data for poziotinib from Cohort 1 during the Keynote Forum at the 11th Annual Congress on Pulmonary & Respiratory Medicine in Amsterdam. The data presentation followed by a conference call to discuss the data and the development strategy for poziotinib had been scheduled for March 18, 2020. Management plans to reschedule the presentation and conference call with investors at an appropriate t
Mar 11, 2020 07:00 am ET
Spectrum Pharmaceuticals to Present Data from Phase 2 Clinical Trial for Poziotinib at Upcoming Medical Conference
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the acceptance for presentation of its abstract of the results for Cohort 1 from its Phase 2 clinical trial, ZENITH20, evaluating poziotinib in previously treated non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations. The abstract, titled “Oral poziotinib shows clinical activity and durable response in previously treated EGFR exon 20 NSCLC patients – a Phase 2 study,” will be part of the Keynote Forum at the 11th Annual
Mar 03, 2020 07:00 am ET
Spectrum Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2020
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at the Barclays Global Healthcare Conference 2020 being held in Miami. The company presentation is scheduled for Tuesday, March 10, 2020, at 4:50 p.m. EDT.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.